Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-20-064857

Executive VP, Head of R&D sold 23,551 shares at an average $149.23 ($3,514,610)

  • Executive VP, Head of R&D acquired 23,551 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Ho Tony W Executive VP, Head of R&D 2020-12-21 Option exercise +23,551 $16.90 $398,012 57,515 D
Ho Tony W Executive VP, Head of R&D 2020-12-21 Sale −1,700 $148.11 $251,787 55,815 D
Ho Tony W Executive VP, Head of R&D 2020-12-21 Sale −900 $149.18 $134,262 54,915 D
Ho Tony W Executive VP, Head of R&D 2020-12-21 Sale −1,600 $150.16 $240,256 53,315 D
Ho Tony W Executive VP, Head of R&D 2020-12-21 Sale −1,100 $151.58 $166,738 52,215 D
Ho Tony W Executive VP, Head of R&D 2020-12-21 Sale −500 $152.41 $76,205 51,715 D
Ho Tony W Executive VP, Head of R&D 2020-12-21 Sale −1,400 $147.05 $205,870 50,315 D
Ho Tony W Executive VP, Head of R&D 2020-12-21 Sale −8,400 $148.38 $1,246,392 41,915 D
Ho Tony W Executive VP, Head of R&D 2020-12-21 Sale −5,000 $149.73 $748,650 36,915 D
Ho Tony W Executive VP, Head of R&D 2020-12-21 Sale −2,951 $150.61 $444,450 33,964 D
Derivatives
Ho Tony W Executive VP, Head of R&D 2020-12-21 Option exercise · Stock Option (right to buy) −23,551 236,449 D
Open-market sales · 23,551 sh · avg $149.23 · $3,514,610
Loading xslF345X03/doc4.xml…